|
Pioglitazone Clinical Trials
10 actively recruiting trials across 4 locations
No change since May 2026
Also known as: Actos, Actos Tab., PIO, actos
Pipeline
Early 1: 1Phase 2: 1Phase 3: 2Phase 4: 4Phase 1/2: 1
Top Sponsors
- The University of Texas Health Science Center at San Antonio4
- University of Florida1
- Stanford University1
- Seoul National University Bundang Hospital1
- Rambam Health Care Campus1
Indications
- Diabetes8
- Type 2 Diabetes3
- Liver Disease2
- Diabetes Mellitus, Type 22
- Type 2 Diabetes (Adult Onset)1
San Antonio, Texas4 trials
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
University Health System Texas Diabetic Institute
Phase 3
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Texas Diabetes Institute/UH
Phase 4
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
The University of Texas Health Science Center at San Antonio
N/A
Quantifying Hepatic Mitochondrial Fluxes in Humans
Texas Diabetes Institute - University Health System
Phase 4
Other3 trials
Palo Alto, California1 trial
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
Stanford University
Phase 4
Gainesville, Florida1 trial
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
University of Florida
Phase 2
Bethesda, Maryland1 trial
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
National Institutes of Health Clinical Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.